奥马珠单抗（抗IgE）治疗哮喘-慢性阻塞性肺疾病重叠综合征（ACOS）及其对循环细胞因子水平的影响。
Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.
作者信息
Yalcin Arzu Didem, Celik Betul, Yalcin Ata Nevzat
机构信息
a Department of Internal Medicine, Clinical Immunology and Allergy Unit , Antalya Research Hospital , Antalya , Turkey ;
b Department of Pathology and Laboratory Medicine , Antalya Research Hospital , Antalya , Turkey ;
出版信息
Immunopharmacol Immunotoxicol. 2016 Jun;38(3):253-6. doi: 10.3109/08923973.2016.1173057. Epub 2016 Apr 28.
CONTEXT
The term "asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome" (ACOS) has been applied to the condition, in which a person has clinical features of both asthma and COPD.
METHODS
The patients (N = 10) were presented to our clinic with low lung function, limited reversibility of airway obstruction, hyperinflation, abnormal body composition, dyspnea and episodic wheezing. Based on the clinical and laboratory findings, the patients were diagnosed with ACOS. Patients' serum IL-2 (sIL-2), sIL-4 sIL-6, sIL-10, sIL-17, sTNF-α and sIFN-γ levels were investigated as an apoptotic marker and a marker for inflammation.
RESULTS
Having undergone omalizumab treatment and a long-term (12 months) later, patients had a decreased IgE, fractional exhaled nitric oxide concentrations (FENO), eosinophil, neutrophils, macrophages, eosinophil cationic peptide (ECP) and sIL-4 levels.
CONCLUSION
To our knowledge, this is the first documentation of omalizumab use in ACOS. We demonstrated decreased IL-4, allergic pulmonary symptoms (dyspnea, wheezing, bronchial hyper responsiveness) and migraine attacks in the patients.
背景
“哮喘-慢性阻塞性肺疾病（COPD）重叠综合征”（ACOS）这一术语已应用于某人同时具有哮喘和COPD临床特征的情况。
方法
10名患者因肺功能低下、气道阻塞可逆性受限、肺过度充气、身体成分异常、呼吸困难和发作性喘息前来我们诊所就诊。根据临床和实验室检查结果，这些患者被诊断为ACOS。对患者血清白细胞介素-2（sIL-2）、sIL-4、sIL-6、sIL-10、sIL-17、可溶性肿瘤坏死因子-α（sTNF-α）和可溶性干扰素-γ（sIFN-γ）水平进行了研究，作为凋亡标志物和炎症标志物。
结果
接受奥马珠单抗治疗并在12个月后，患者的免疫球蛋白E（IgE）、呼出一氧化氮分数浓度（FENO）、嗜酸性粒细胞、中性粒细胞、巨噬细胞、嗜酸性粒细胞阳离子蛋白（ECP）和sIL-4水平均有所下降。
结论
据我们所知，这是奥马珠单抗用于ACOS的首次记录。我们证明了患者的白细胞介素-4、过敏性肺部症状（呼吸困难、喘息、支气管高反应性）和偏头痛发作均有所减少。
Zotero 插件